Novartis presents positive long-term data for relapsing MS treatment Kesimpta
Novartis has announced positive long-term data from an open-label extension (OLE) study of its multiple sclerosis (MS) treatment, Kesimpta (ofatumumab). Results from the ALITHIOS OLE showed sustained efficacy of first-line and continuous treatment with the …